<DOC>
	<DOC>NCT01298518</DOC>
	<brief_summary>PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.</brief_summary>
	<brief_title>A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male and/or female subjects between the ages of 18 and 60 years; Body Mass Index (BMI) of &gt;25.0 kg/m2 and &lt;40 kg/m2; Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines; Subjects who have been on welltolerated and stable doses of metformin Recent evidence (6 months prior to screening) or history of unstable major organ disease; Diagnosis of Type 1 diabetes mellitus; Current medical history of myocardial infarction, unstable angina, or history of stroke (including TIA) within 6 months prior to Screening; Treatment with thiazolidinediones (TZDs), or subcutaneously administered antidiabetic agents;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>multiple dose study in type 2 diabetes patients</keyword>
</DOC>